Psychiatric Quarterly [psaq] ph183-psaq-460944 June 5, 2003 13:26 Style ﬁle version June 4th, 2002
Psychiatric Quarterly, Vol. 74, No. 3, Fall 2003 (
METABOLIC CONSEQUENCES OF
ATYPICAL ANTIPSYCHOTIC DRUGS
Harold E. Lebovitz, M.D.
Atypical antipsychotic drugs have become the treatment of choice for psychotic
disorders. However, these medications, though certainly superior in many re-
spects to the more traditional medications, have been shown to have a number
of untoward consequences. Understanding of the metabolic consequences of
these medications is essential for the psychiatrist. The possible development
of diabetes, weight gain, and hypertriglyceridemia in patients taking atypical
antipsychotics makes it imperative that the prescribing physician regularly
monitor patients on these agents. One possible monitoring scheme is outlined
and recommendations for treatment are discussed.
KEY WORDS: diabetes; atypical antipsychotics; hypertriglyceridemia.
The development of the new class of atypical antipsychotic drugs has
brought about dramatic improvement in the function of many patients
with schizophrenia and related mental disorders. Following the in-
troduction of these agents into the market place, however, a number
of case reports appeared in the literature suggesting that treatment
with these agents is associated with an increase in obesity, clinical
Harold E. Lebovitz, M.D. is Professor of Medicine, Department of Medicine, State
University of New York Health Science Center at Brooklyn.
Address correspondence to Harold E. Lebovitz, M.D., 416 Henderson Ave., Staten
Island, NY 10310; e-mail: firstname.lastname@example.org.
2003 Human Sciences Press, Inc.